Drug−Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development
Top Cited Papers
- 12 December 2003
- journal article
- review article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 17 (1), 3-16
- https://doi.org/10.1021/tx034170b
Abstract
It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity. Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Laboratories has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage. This requires a flexible approach to defining bioactivation issues in a variety of metabolism vectors and typically involves the initial use of small molecule trapping agents to define the potential for bioactivation. At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) preparations from preclinical species and human, and also in vivo, typically in the rat. This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Laboratories. The availability of a dedicated Labeled Compound Synthesis group, coupled to a close working relationship between Drug Metabolism and Medicinal Chemistry, represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.Keywords
This publication has 20 references indexed in Scilit:
- Metabolic Activation of a Pyrazinone-Containing Thrombin Inhibitor. Evidence for Novel Biotransformation Involving Pyrazinone Ring Oxidation, Rearrangement, and Covalent Binding to ProteinsChemical Research in Toxicology, 2003
- Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniquesJournal of Mass Spectrometry, 2003
- Selective Protein Covalent Binding and Target Organ ToxicityToxicology and Applied Pharmacology, 1997
- Specificity of in vitro Covalent Binding of Tienilic Acid Metabolites to Human Liver Microsomes in Relationship to the Type of Hepatotoxicity: Comparison with Two Directly Hepatotoxic DrugsChemical Research in Toxicology, 1994
- Diclofenac Covalent Protein Binding Is Dependent on Acyl Glucuronide Formation and Is Inversely Related to P450-Mediated Acute Cell Injury in Cultured Rat HepatocytesToxicology and Applied Pharmacology, 1993
- Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.JCI Insight, 1988
- Comparison of ratios of covalent binding to total metabolism of the pulmonary toxin, 4-ipomeanol, In vitro in pulmonary and hepatic microsomes, and the effects of pretreatments with phenobarbital or 3-methylcholanthreneBiochemical and Biophysical Research Communications, 1980
- Hepatic sensitivity to imipramineDigestive Diseases and Sciences, 1977
- Biochemical Mechanisms of Drug ToxicityAnnual Review of Pharmacology, 1974
- Carcinogenic Activity, Structure, and Chemical Reactivity of Polynuclear Aromatic HydrocarbonsThe American Journal of Cancer, 1938